The United States Food and Drug Administration (FDA) has issued another round of legal warnings to companies marketing products that contain cannabidiol (CBD), a compound found in marijuana.
The FDA issued similar warning letters to six companies last year.
The warning letters criticize the products for not containing the amount of CBD they claim to. They also take aim at health claims the companies have made about those products.
As Alan Brochstein explains in New Cannabis Ventures, companies are prohibited from making health claims unless the product was marketed before GW Pharma published clinical trials.
The FDA considers CBD to be a “new drug” and not a dietary supplement. Therefore, CBD products must be used under the supervision of a doctor and cannot be sold as supplements, according to FDA regulations.
In : Cannabis Regulation